Many studies have found that injection of self-complementary scAAV9 vectors expressing full-length human SMN protein in various mouse models of severe SMA significantly increased their lifespan and reduced disease severity [21,22]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.